Quince Stock Price, News & Analysis

Quince Therapeutics (Nasdaq: QNCX), a late-stage biotechnology company focused on rare disease treatments, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The company's CEO and CMO, Dr. Dirk Thye, will deliver a presentation that will be available on September 5, 2025, at 7:00 a.m. ET.

Investors can access the presentation webcast through Quince's Investor Relations website at ir.quincetx.com, with an archive available after the event.

Quince Therapeutics (Nasdaq: QNCX) announced significant progress in Q2 2025, highlighted by the completion of enrollment in its pivotal Phase 3 NEAT clinical trial for A-T treatment. The trial enrolled 105 participants, with topline results expected in Q1 2026. The company secured financing that brought its cash position to $34.7 million, providing runway through Phase 3 results into Q2 2026.

Key financial results include R&D expenses of $6.6 million, G&A expenses of $3.3 million, and a net loss of $16.1 million ($0.34 per share). Quince entered a strategic partnership with Option Care Health for U.S. commercial launch support and closed a premium-priced private placement led by Nantahala Capital, generating $11.5 million in upfront proceeds with potential additional proceeds of up to $10.4 million from warrants.

Quince Therapeutics (Nasdaq: QNCX) has established a strategic partnership with Option Care Health (Nasdaq: OPCH) for the commercial development and launch of its lead asset, encapsulated dexamethasone sodium phosphate (eDSP) in the United States.

Option Care Health will provide nationwide specialty pharmacy and infusion services through its network of 90+ pharmacies and 180+ ambulatory infusion suites. The partnership aims to enhance access to eDSP treatment for patients with Ataxia-Telangiectasia (A-T), with potential expansion to treat Duchenne muscular dystrophy (DMD).

The collaboration includes comprehensive services such as logistics management, patient registration, hub support, clinician-delivered services, and data reporting to support eDSP's commercial launch, pending positive study results and regulatory approval.

Quince Therapeutics (Nasdaq: QNCX) has completed enrollment in its pivotal Phase 3 NEAT clinical trial evaluating eDSP for treating Ataxia-Telangiectasia (A-T), a rare neurodegenerative disease. The trial has enrolled 105 total participants, including 83 in the primary analysis population (ages 6-9) and 22 participants aged 10 or older.

The study, conducted under a Special Protocol Assessment agreement with the FDA, features a 90% statistical power for the primary endpoint. Quince expects to report topline results in Q1 2026 and plans to submit a New Drug Application to the FDA in H2 2026. The company's eDSP System has received FDA Fast Track designation, highlighting its potential to address high unmet medical needs in A-T treatment.

Quince Therapeutics (Nasdaq: QNCX) has appointed Dr. Hassan Abolhassani to its Scientific Advisory Board (SAB) as its ninth member. Dr. Abolhassani, an Assistant Professor at the Karolinska Institutet, is a leading immunologist recognized in the top 1% of highly cited researchers in immunology.

The appointment strengthens Quince's SAB as the company advances its lead asset eDSP, currently in a Phase 3 clinical trial for Ataxia-Telangiectasia (A-T). The company expects to report topline results in Q1 2026. Beyond A-T and Duchenne muscular dystrophy, Quince is exploring 11 additional rare disease indications for eDSP where corticosteroid treatment could be beneficial without associated toxicities.

Quince Therapeutics (Nasdaq: QNCX) announced its participation in the 2025 A-T Clinical Research Conference from June 25-27, 2025, at Loughborough University, UK. Key opinion leaders will present post hoc analyses from the Phase 3 ATTeST trial of eDSP, their lead asset for Ataxia-Telangiectasia (A-T) treatment.

The company reported 99 total participants enrolled in their pivotal Phase 3 NEAT clinical trial, including 78 participants aged 6-9 years and 21 participants aged 10 or older. All 42 NEAT participants have opted for the open-label extension study. The company expects to report topline results in Q1 2026 with potential NDA submission in H2 2026.

Notable findings include no serious metabolic or endocrine events in 68 A-T patients treated with eDSP for two years or longer, and the presence of miniATM genes in 40% of patients, correlating with disease severity at baseline.

Quince Therapeutics (QNCX) has closed a private placement of securities worth up to $22 million, priced at a premium. The financing includes $11.5 million in upfront proceeds and potential additional proceeds of $10.4 million from warrant exercises. Led by Nantahala Capital, with participation from ADAR1 Capital Management and company management, the funding extends cash runway through Q2 2026. The company's Phase 3 NEAT trial for Ataxia-Telangiectasia (A-T) has enrolled 95 participants, with topline results expected in Q1 2026. The trial evaluates eDSP, their lead asset which delivers corticosteroid efficacy without toxicity. The FDA has granted Fast Track designation for eDSP in A-T treatment. Funds will support trial completion, pipeline expansion into Duchenne muscular dystrophy, and other rare disease indications.

Quince Therapeutics (QNCX) has secured a private placement of securities expected to generate $11.5 million in upfront proceeds, with potential additional proceeds of up to $10.4 million through warrant exercises. The financing, led by Nantahala Capital with participation from ADAR1 Capital Management and company management, is priced at $1.325 per share, a 10% premium over the previous closing price. The company will issue 8,671,928 shares of common stock with accompanying warrants exercisable at $1.20 per share. The proceeds will fund the ongoing Phase 3 NEAT clinical trial in Ataxia-Telangiectasia, along with general corporate expenses. Combined with existing funds, this financing is expected to extend Quince's operations into Q2 2026, or H2 2026 if warrants are fully exercised.

Quince Therapeutics (QNCX) has achieved over 75% enrollment in its pivotal Phase 3 NEAT clinical trial for Ataxia-Telangiectasia (A-T), a rare neurodegenerative disease. The trial has enrolled 76 participants total, with 65 in the primary analysis group (ages 6-9) out of a target of 86 participants. The study shows strong progress with an 80% power rate and low 10% screen failure rate among 108 screened participants. All 37 eligible participants have opted for the open-label extension study. The trial evaluates eDSP, which has received FDA Fast Track designation, through a randomized, double-blind, placebo-controlled study with six infusions over 21-30 days. Pending positive results, Quince plans to submit an NDA to the FDA in H2 2026.